**KR-33493**

**Cat. No.:** HY-100755  
**CAS No.:** 1021497-97-1  
**Molecular Formula:** C₂₀H₁₈BrN₃O₃S  
**Molecular Weight:** 460.34  
**Target:** Others  
**Pathway:** Others  
**Storage:**  
- Powder: -20°C 3 years, 4°C 2 years  
- In solvent: -80°C 6 months, -20°C 1 month

**SOLVENT & SOLUBILITY**

In Vitro  
DMSO: $\geq$ 31 mg/mL (67.34 mM)  
*“$\geq$” means soluble, but saturation unknown.*

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>Mass 1 mg</th>
<th>Mass 5 mg</th>
<th>Mass 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.1723 mL</td>
<td>10.8615 mL</td>
<td>21.7231 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4345 mL</td>
<td>2.1723 mL</td>
<td>4.3446 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2172 mL</td>
<td>1.0862 mL</td>
<td>2.1723 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**BIOLOGICAL ACTIVITY**

**Description**  
KR-33493 is a potent inhibitor of Fas-mediated cell death (FAF1).

**IC₅₀ & Target**  
FAF1[1]

**In Vivo**  
Body weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. The dose-normalized AUC_{last} is not significantly different between the groups, suggesting that KR-33493 is governed by linear kinetics[1].
Animal Administration[1]

A total of 93 male and 93 female specific pathogen-free rats (6 weeks of age), and 16 male and 16 female beagle dogs (8 months of age) are used in this study. In a toxicokinetic study, rat blood samples (approximately 0.6 mL) are collected into tubes containing heparin from the lateral tail vein at 0, 0.5, 1, 2, 4, 8, 12, and 24 h after dosing with KR-33493 at doses of 50, 150, and 500 mg/kg/day on Day 1 and Week 4. Dog blood samples (approximately 0.6 mL) are collected into tubes containing EDTA-2K from the cephalic vein at 0, 0.5, 1, 2, 4, 6, 8, and 24 h after dosing at KR-33493 doses of 50, 250, and 1000 mg/kg/day on Day 1 and Week 2. The plasma is separated by centrifugation (approximately 132,000 g, 3 min, 4°C) and stored at approximately -80°C until analysis. The KR-33493 concentration in plasma is quantified[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES